What is the difference between somatic and germline mutations in Lung Cancer

Somatic vs. Germline Mutations in Lung Cancer

This is an important distinction that affects how your cancer is treated and whether your family members might be at risk. Let me break down the difference:

Somatic Mutations (Most Common in Lung Cancer)

What they are: Mutations that develop only in the cancer cells themselves, usually during a person's lifetime. These mutations are acquired—not inherited.

Key characteristics:

• Occur in the tumor tissue only
• Result from environmental exposures (like smoking, secondhand smoke, radon, or air pollution)
• Cannot be passed to children or family members
• Account for the majority of lung cancers
• Examples in lung cancer: EGFR mutations, KRAS mutations, ALK rearrangements, PD-L1 expression

Why it matters: Somatic mutations are often targetable—meaning doctors can use specific drugs designed to attack cancer cells with these particular mutations. This is why genetic testing of your tumor is so important.

---

Germline Mutations (Less Common, But Important)

What they are: Mutations present in every cell of your body from birth, inherited from one or both parents. These are in your DNA from the start.

Key characteristics:

• Present in all cells (cancer and normal cells)
• Inherited from parents; can be passed to children
• Increase lifetime risk of developing cancer
• Examples: BRCA1/BRCA2, TP53, EGFR germline mutations
• Account for a smaller percentage of lung cancers

Why it matters:

• If you have a germline mutation, your family members may also carry it and should consider genetic counseling
• Affects treatment decisions and surveillance recommendations
• May influence screening recommendations for relatives

---

How Doctors Distinguish Between Them

Your oncology team typically tests the tumor tissue (somatic mutations) to guide treatment decisions. If certain patterns emerge, they may recommend germline testing (blood test) to check if you inherited a cancer-predisposition mutation.

According to NCCN Guidelines for Non-Small Cell Lung Cancer, molecular testing of the tumor for somatic mutations like EGFR, ALK, ROS1, BRAF, KRAS, MET, NTRK, and PD-L1 is standard practice to guide targeted therapy and immunotherapy decisions.

---

Questions to Ask Your Oncologist

1. "Has my tumor been tested for somatic mutations? Which ones?"
2. "Based on my results, am I a candidate for targeted therapy?"
3. "Do you recommend germline genetic testing for me or my family?"
4. "If I have a germline mutation, what does that mean for my family members?"
5. "Should I see a genetic counselor?"

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.